Valvira (the National Supervisory Authority for Welfare and Health) directs and supervises the biobank activity in Finland, and maintains a national biobank register. Before starting to operate the biobank has to obtain a licence from Valvira.
Valvira has granted a licence altogether to nine biobanks, from which three are operating in the whole of Finland and six biobanks in the area of hospital districts.
Picture: Finnish biobanks. Regional biobanks collect samples in the area of hospital districts and country-wide biobanks in the whole of Finland.
Auria Biobank is the first clinical biobank established in Finland. Auria Biobank has been established by the University of Turku and the hospital districts of Southwest Finland, Satakunta and Vaasa. Approximately 80% of the samples in Auria Biobank are cancer samples. In accordance with the specialities of the hospital districts of Southwest Finland and Satakunta, the biobank supports research in cancer, diabetes and cardiovascular diseases in particular. Auria Biobank obtained a licence to operate from the National Supervisory Authority for Welfare and Health, Valvira on March 10, 2014.
Lila Kallio, Head of Auria Biobank, tel. +358-50 578 0815
THL Biobank belongs to the National Institute for Health and Welfare. THL Biobank’s registered areas of research include population’s health promotion, identification of factors involved in disease mechanisms, and disease prevention. THL Biobank is a country-wide biobank and hosts a remarkable collection of population and disease-specific samples for research purposes. The National Supervisory Authority for Welfare and Health (Valvira) granted THL Biobank a licence to operate on 10 March 2014.
Anu Jalanko, PhD, Adjunct Professor, THL Biobank, tel. +358-29-524 8392
e-mail: email@example.com, biopankki [at] thl.fi
Hematological Biobank is owned by the Finnish Association of Hematology, Institute for Molecular Medicine Finland and Finnish Red Cross Blood Service. The Association of Finnish Cancer Patients is also involved in Hematological Biobank. Biobanks’s research area covers the prevention, diagnosis, treatment and follow-up of hematological disorders. Hematological Biobank is a national biobank and collects samples and data from patients with hematological disorder in all Finnish hematological units that have made an agreement on sample collection. The aim of the Hematological Biobank is to collect a comprehensive and high quality sample and data repository for hematology research. The Hematological Biobank was registered in Valvira’s (National Supervisory Authority for Welfare and Health) national biobank registry on July 15, 2014.
Kimmo Porkka, Principal Investigator
Helsinki University Central Hospital (HUCS) -area of special responsibility and the University of Helsinki have established a clinical biobank that supports the translational research done in the region, and network with national and international biobanks. The research field of Helsinki Biobank is the research done in health and medical science in HUCS area. Helsinki Biobank operates to support research which aims at promoting population health, understanding the factors in disease mechanisms or the development of health care products. The biobank obtained a licence to operate from the National Supervisory Authority for Welfare and Health, Valvira on April 21, 2015.
Kimmo Pitkänen, Head of Helsinki Biobank, tel. +358-50-575 8579
Northern Ostrobothnia Hospital District (PPSHP), the University of Oulu (UO), Nordlab and the hospital/healthcare districts of Lapland, Länsi-Pohja, Central Ostrobothnia and Kainuu have established a biobank in Northern Finland. The Biobank Borealis obtained a licence to operate from Valvira on July 10, 2015.
Saila Kauppila, Adjunct Professor, Biobank Director, tel. +358-8-315 2090
Pia Nyberg, Project Manager, tel. +358-400-461 349
e-mail: firstname.lastname@example.org, biopankkiborealis [at] ppshp.fi
Finnish Clinical Biobank Tampere (FCBT) was established by Pirkanmaa Hospital District, University of Tampere, Etelä-Pohjanmaa Hospital District and Kanta-Häme Hospital District. FCBT’s role is to support disease prevention, studies on the effectiveness or side effects of treatment of patients, and studies exploiting pathological findings. The main focus of the biobank, in accordance with the research strategy defined by the University of Tampere and Pirkanmaa Hospital District, is research in cardiovascular disease, cancer, immunology and type 1 diabetes. FCBT’s licence to operate was granted by the National Supervisory Authority for Welfare and Health, Valvira, on September 8th, 2015.
The aim is to start sample collection gradually during 2016.
Kimmo Savinainen, Head of Tampere Biobank, tel. +358-50-590 7515
e-mail: email@example.com, biopankki [at] tays.fi
The Biobank of Eastern Finland was established by the hospital district of North Savo, The South Savo Social and Health Care Authority, the hospital district of Eastern Savo, Siun sote – Joint municipal authority for North Karelia social and health services and the University of Eastern Finland. The Biobank of Eastern Finland aims to mediate high quality human samples to medical research to promote development of new products and services that promote public health. The Biobank of Eastern Finland was registered to Valvira national biobank register on October 29, 2015.
Hanna Tuhkanen, PhD, Research Coordinator, tel. +358-40-717 9960
The Central Finland Hospital District and the University of Jyväskylä established a biobank in Jyväskylä that aims to promote research and to support the development of diagnostics and treatment. The Central Finland Biobank was registered to Valvira national biobank register on October 29, 2015.
Marjukka Friman, Production Manager, tel. +358-14-269 5782